Transdermal cold atmospheric plasma-mediated immune checkpoint blockade therapy

TitleTransdermal cold atmospheric plasma-mediated immune checkpoint blockade therapy
Publication TypeJournal Article
Year of Publication2020
AuthorsChen, Guojun, Zhitong Chen, Di Wen, Zejun Wang, Hongjun Li, Yi Zeng, Gianpietro Dotti, Richard E. Wirz, and Zhen Gu
JournalProceedings of the National Academy of Sciences
Start Page3687
Date Published02/2020
AbstractDespite the promise of immune checkpoint blockade (ICB) therapy against cancer, challenges associated with low objective response rates and severe systemic side effects still remain and limit its clinical applications. Here, we described acold atmospheric plasma (CAP)-mediated ICB therapy integrated with microneedles (MN) for the transdermal delivery of ICB. We found that a hollow-structured MN(hMN) patch facilitates the transportation of CAP through the skin, causing tumor cell death. The release of tumor-associated antigens then promotes the maturation of dendritic cells in the tumor-draining lymph nodes, subsequently initiating T cell-mediated immune response. Anti-programmed death-ligand 1 antibody (aPDL1), an immune checkpoint inhibitor, released from the MN patch further augments the antitumor immunity. Our findings indicate that the proposed transdermal combined cap and ICB therapy can inhibit the tumor growth of both primary tumors and distant tumors, prolonging the survival of tumor-bearing mice.

Download File (pdf)

This publication may be downloaded for personal use only. Any other use requires prior permission of the authors and publisher.